Review

Multi-Valent Protein Hybrid Pneumococcal Vaccines: A Strategy for the Next Generation of Vaccines

Ninicia R. Scott 1, Beth Mann 2, Elaine I. Tuomanen 2 and Carlos J. Orihuela 1,*

1 Department of Microbiology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA; nrscott@uab.edu
2 Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA; beth.mann@stjude.org (B.M.); elaine.tuomanen@stjude.org (E.I.T.)
* Correspondence: corihuel@uab.edu

Abstract: Streptococcus pneumoniae (Spn) is a bacterial pathogen known to colonize the upper respiratory tract and cause serious opportunistic diseases such as pneumonia, bacteremia, sepsis and meningitis. As a consequence, millions of attributable deaths occur annually, especially among infants, the elderly and immunocompromised individuals. Although current vaccines, composed of purified pneumococcal polysaccharide in free form or conjugated to a protein carrier, are widely used and have been demonstrated to be effective in target groups, Spn has continued to colonize and cause life-threatening disease in susceptible populations. This lack of broad protection highlights the necessity of improving upon the current “gold standard” pneumococcal vaccines to increase protection both by decreasing colonization and reducing the incidence of sterile-site infections. Over the past century, most of the pneumococcal proteins that play an essential role in colonization and pathogenesis have been identified and characterized. Some of these proteins have the potential to serve as antigens in a multi-valent protein vaccine that confers capsule independent protection. This review seeks to summarize the benefits and limitations of the currently employed vaccine strategies, describes how leading candidate proteins contribute to pneumococcal disease development, and discusses the potential of these proteins as protective antigens – including as a hybrid construct.

Keywords: Streptococcus pneumoniae; pneumococcal vaccine; hybrid vaccine

1. Introduction

Streptococcus pneumoniae (Spn; the pneumococcus) is an encapsulated Gram-positive bacterium that colonizes the human nasopharynx. It is an opportunistic pathogen that primarily causes disease in infants, the elderly, those who are immunocompromised or have underlying co-morbidities, and individuals with ongoing or recent viral infection of the respiratory tract [1–5]. Once established in the nasopharynx, Spn is capable of causing localized inflammation of the upper-respiratory tract resulting in sinusitis, ascending the Eustachian tubes to cause otitis media, being aspirated to cause pneumonia, and, once in the lower respiratory tract, escaping into the bloodstream to cause bacteremia/sepsis and disseminated organ damage including meningitis (Figure 1). Although the incidence rates of Spn disease following colonization are overall quite low [6], such a large number of individuals are colonized that the total disease burden is staggering. It has been estimated that the pneumococcus is responsible for ~300,000 deaths in children per year and as much as 1.5 million deaths annually worldwide [7,8]. For these reasons the World Health Organization has designated Spn as a priority pathogen.
Figure 1. Pneumococcal pathogenesis. *Streptococcus pneumoniae* (*Spn*) pathogenesis begins with successful colonization of the nasopharynx, where it typically resides asymptomatically. Given the opportunity, particularly in those who have recently experienced viral infection or are immunocompromised, *Spn* can cause localized disease in the middle ear (otitis media) and in the lungs (pneumonia). Failure to control these infections, allows *Spn* to escape into the bloodstream (bacteremia) and cause sepsis, systemic disseminated organ damage, which includes the heart, and central nervous system.

**Pneumococcal Capsule**

Capsular polysaccharide is a principal and well characterized virulence determinant of *Spn*. Composed of repeating oligosaccharide units, at this point in time, 100 biochemically and serologically distinct forms of capsule (i.e. serotypes) are known to exist [9]. Capsule has multiple roles in regard to the biology and pathogenesis of *Spn* [10]. The negative charge of capsule electrostatically repels glycans that are part of mucus, helping to prevent bacterial entrapment and expulsion from the respiratory tract [11]. Capsule is hydrophilic in nature and this confers protection against desiccation during transmission on fomites [12]. Perhaps in its most characterized role, capsule inhibits phagocytosis by immune cells [13]. Capsule does so by inhibiting complement deposition and blocking interactions of receptors on phagocytes, e.g. Fc receptor, with opsonic host proteins bound to the bacterial cell wall or its surface proteins [13]. In similar fashion, capsule has been shown to downmodulate the inflammatory response of immune and non-immune cells by preventing the engagement of Toll-like receptors with PAMPs (pathogen associated molecular patterns) present on the bacterial surface and thereby, dampening *MyD88* downstream signaling and inflammatory cytokine production [14]. As result of its ability to block opsonophagocytosis, *Spn* requires the capsule to survive in the bloodstream, and with extremely rare exception, almost all invasive isolates of *Spn* are encapsulated [15,16]. Since capsule covers the surface of the pneumococcus, antibodies against capsule are highly opsonic, albeit only to *Spn* that produce the capsule type to which the antibody was generated [17,18]. In the bloodstream, where pneumococci must be encapsulated to avoid clearance by immune cells, anti-capsular antibodies are therefore highly protective against invasive disease caused by strains that carry the corresponding serotype. It is for this reason vaccines against *Spn* are currently designed to elicit antibodies against the serotypes most often associated with severe human disease.

2. The Rationale for Capsule-based Vaccines and Their Success

Due to the considerable morbidity and mortality associated with pneumococcal disease, vaccine-based efforts to prevent disease have been ongoing since 1911 [19,20]. Initial vaccines were whole cell-based, involving immunization with heat-killed bacteria belonging to serotype 1, which afflicted mine workers in South Africa [20]. Ultimately, work by MacLeod et al. demonstrated that immunization with capsular polysaccharide conferred
protection against disease, and thereafter, vaccine formulations shifted towards the use of purified capsular polysaccharide [21]. Notably and since each serotype is biochemically and antigenically distinct, comprehensive capsule-based immunization coverage against *Spn* would require immunization with the majority of the 100 serotypes that currently exist—which is far too numerous to be feasible. Instead, the vaccines that are currently used against *Spn* are composed of purified capsular polysaccharide from a limited number of serotypes most commonly responsible for human disease [22]. Currently, there are two types of vaccines containing capsular polysaccharides that are approved by most licensing agencies: one composed of 23 purified capsules (PPSV) and, the other composed of 7, 10, or 13 purified capsules conjugated to a protein carrier (PCV) [22,23].

2.1. Pneumococcal Polysaccharide Vaccine: PPSV23

PPSV23 was licensed by the U.S. Federal Drug Administration in 1983. It consists of capsules from serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F [22]. The serotypes incorporated into this vaccine accounted for 60–70% of *Spn* serotypes that caused invasive pneumococcal disease specifically in developed countries [19]. PPSV23 has been shown to be up to 65% effective against invasive pneumococcal disease but does not have demonstrable protection against colonization or pneumonia [19,24]. As a result of the former, it does not negatively impact transmission nor promote herd immunity. Conventionally, polysaccharides are poor stimulators of the adaptive immune system. *Spn* capsular polysaccharides are no different and this is the greatest limitation of PPSV. Given that capsule is a carbohydrate, it is not presented to T-cells in an major histocompatibility complex (MHC) class II dependent manner by antigen-presenting cells (i.e. capsules are a T-cell independent antigens). The consequence of this is that children under the age of 2 years, one of the highest risk groups, fail to elicit an effective protective immunological response to PPSV [25]. In adults, the absence of CD4+ cell generated immunity results in the lack of a memory response, thus immunity wanes within 5 years.

2.2. Polysaccharide Conjugate Vaccines: PCV7,10, and 13

In order to protect young children and influenced by the success of the polysaccharide conjugate vaccine against *Haemophilus influenzae* type B (HiB) licensed in 1985, polysaccharide conjugate vaccines (PCV) for *Spn* were developed [26]. The fundamental difference between PCV and PPSV is that the polysaccharide capsule is conjugated to a protein carrier in PCVs. The attachment to a protein alters antigen processing within the cells such that the polysaccharide is processed and presented with a fragment of the protein by MHC II and this results in a protective T-cell dependent antibody response against the capsule type [19]. In contrast to PPSV, PCVs protect children under the age of 2 years and elicit long-lasting immunity. The first PCV, PCV7, which covered seven serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) was licensed in the U.S. in 2000 for use in children and dramatically reduced all pneumonia-based hospitalizations by 39–52% [19,22,27–29]. A 2007 study in Spain demonstrated that PCV7 was 31% effective against pneumonia and reduced pneumococcal invasive disease by 88% [30]. Strikingly, the efficacy of PCV7 in children under the age of 2 years was 80–90% [31]. Importantly, the robust immunogenicity of PCV7 resulted in sufficiently high levels of IgG antibody against capsule in salivary mucosal secretions to prevent colonization of pneumococci from the nasopharynx of children, the reservoir of *Spn*. This, in turn, reduced transmission and led to a decline in disease in unvaccinated adults, a phenomenon known as herd immunity [32]. In 2010, PCV10 and PCV13 vaccines were introduced to expand coverage to 10 (PCV7 and 1, 5, and 7F) and 13 serotypes (PCV10 and serotypes 3, 6A,19A) [19,22]. These next generation products retain the advantages of conjugate vaccines and are the standard of efficacy upon which all other vaccines will be judged.

Adults over the age of 65 years are recommended to receive pneumococcal vaccination and either the 23-valent capsule based non-conjugate vaccine or PCV13 can be used
at the choice of the medical provider. The clinical target of vaccination is pneumococcal pneumonia and, in both cases, the protective immune response is serotype specific. For both vaccines, the overall rates of invasive disease and bacteremic pneumonia in elderly adults were decreased by 50–75% but there was no protection against community acquired pneumonia. The poor activity of capsule-based vaccines of all types in preventing respiratory infection is a major shortcoming that is important for newer vaccines to address[33].

3. Limitations of Polysaccharide-based Vaccines

Since there are 100 Spn serotypes, a 13-valent or 23-valent vaccine targets only a small subset of possible clinical strains. While there will be more complex PCVs in the future, there is a physical limit to the number of serotypes that can be formulated into one vaccine and concerns exist that serotype expansion will reduce the response to each individual capsule type due to in host competition for specific T-cells capable of recognizing the protein component of the vaccine [34]. While it would enhance overall protection, creation of geographically specific combinations of capsule into separate vaccines would increase costs and vaccinated populations would remain subject to serotype replacement and the other limitations described below. The development of a pneumococcal vaccine that is not solely capsule dependent can potentially offer progress past escape from vaccine coverage and provide protection for a broader susceptible population.

3.1. Serotype Replacement

Serotype replacement is a process whereby non-vaccine serotypes emerge and move into the niche previously occupied by the vaccine-covered serotypes. It had been hoped that since the 93 non-vaccine serotypes were not as frequent a cause of infection as those covered by PCV7, that they would be less virulent and remain less frequent. This proved inaccurate and the genetic content of emerging serotypes showed no loss of virulence traits [35]. The most prominent example of serotype replacement occurred within four years after PCV7 was introduced. During 2000 to 2004, the yearly incidence for serotype 19A climbed from 2.5/100,000 to 7.8/100,000 [36]. To counter this threat, expanded coverage PCV13, including serotype 19A, was deployed and vaccine efficacy rebounded to 80-82% [31]. However, serotype 35B infection rates are now increasing [37]. It can be hypothesized that serotype replacement will occur each time a new polysaccharide conjugate is developed; thus making it imperative to have a vaccine strategy that circumvents vaccine escape [22].

3.2. Antibiotic Resistance

Antibiotic resistance is a relentless concern as pneumococci are naturally competent for DNA exchange and readily acquire resistance to beta lactams, macrolides, fluoroquinolones and vancomycin. This dangerously compromises treatment of the most severe infections, particularly meningitis. The deployment of vaccines has slowed the spread of antibiotic resistance as shown by the decrease in pneumococcal infections by strains resistant to any antibiotic from 7/100,000 to 3/100,000 after PCV7 was introduced in 2000 [38]. As resistance tends to occur in specific serotypes, inclusion of these in vaccine formulations has made a major impact on eliminating resistance. For example, PCV7 successfully targeted over 80% of infections by resistant strains. Beginning in 2010, serotype 19F emerged to cause 30% of resistant infections and addition of this serotype to PCV13 significantly decreased resistant infection. However, just as with serotype replacement, adding capsule types to increasingly complex vaccine formulations is not a long term solution to controlling the threat of antibiotic resistance.
3.3. Capsule Shedding and Phase Variation

The success of capsule based vaccines against invasive disease is unfortunately counterbalanced by weak efficacy at mucosal sites, such as for pneumonia and otitis media. Like many other successful bacterial pathogens, Spn undergoes phase variation during which surface components, such as capsule, shift stochastically from high to low levels of expression. The frequency of specific phase-variants in distinct anatomical sites in turn being the result of anatomical-site specific selective pressures in the host environment [39]. Bacteria on the mucosal surface have been shown to be less encapsulated than blood-isolated counterparts, thereby exposing surface adhesins, and thus antibodies directed at capsule are at a disadvantage in promoting opsonophagocytosis at the mucosal level. In addition to this genetic adaptation to a niche, a newly recognized phenomenon of capsule shedding also decreases the efficacy of anti-capsular antibodies [40]. Upon entering the lung, Spn encounters antimicrobial peptides and as a defense, the bacteria shed most of their capsule over several hours. This floods the pulmonary milieu with detached capsule and simultaneously reveals surface proteins that interact with host cells promoting Spn invasion. Antibodies to capsule are thus consumed by this diversion and rendered ineffective.

3.4. Serotype 3

Serotype 3 is a particular problem and merits discussion. Notably, the incidence of disease caused by serotype 3 isolates has not declined despite its inclusion in the 13-valent PCV vaccine. Serotype 3 produces profuse quantities of capsule, resulting in a “wet” or mucoid appearance when grown on agar plates. Unlike the vast majority of other serotypes, serotype 3 capsule is not covalently attached to the bacterial surface and therefore is constantly released into the milieu. Similar to shedding of covalently attached capsule by LytA, unbound serotype 3 capsule effectively binds capsular antibody at a distance, away from the bacteria, and therefore negates opsonization [41]. Choi et al. assessed the serotype specific protective effects of PCV-13. It was shown that 0.2 μL of serotype 3 bacterial culture supernatant was sufficient to overwhelm the protective effect of the vaccine-induced antibody in passively immunized mice, a value 100 times more effective at neutralizing anti-capsular antibody than serotype 4 [42]. It was estimated that eight times more antibody is needed to be generated by PCV in order to induce protection against serotype 3 invasive disease [42,43]. Notably disease caused by serotype 3 Spn is particularly severe including complications of pneumonia and adverse cardiac events being independently associated with this serotype [44–46].

3.5. The Elderly Are Highly Susceptible to Pneumococcal Disease

Individuals 65 years and older are particularly susceptible to severe pneumococcal disease and the relative prevalence of specific serotypes differs from that in children [2]. Among adults, Spn is responsible for ~37% of all community acquired pneumonia [47], with a stunning >84% of all Spn associated mortality occurring among the elderly [48]. The reasons for this increased susceptibility are multifaceted and include structural changes to the respiratory tract, increased frequency of underlying co-morbidities, and changes to both the innate and adaptive immune system that include general declines of protective humoral memory [2]. In adults, as well as children, viral infection, such as influenza, primes the respiratory system for a secondary bacterial infection, most often Spn [49]. It is notable that considerable documentation exists supporting the notion that immunization of seniors with PCV23 offers some protection against secondary pneumonia, but that protection is further increased when influenza vaccine is administered together [50]. Altogether, the elderly are at greater risk for opportunistic infection with a much broader range of pneumococcal serotypes than those which cause disease among younger adults.
as result of a generally less robust immune system [51,52]. A vaccine that confers protection to the elderly must therefore be efficacious against more than the 13 serotypes currently in PCV13.

4. Advantages of Multiprotein-based Vaccines

Although the current capsule-based pneumococcal vaccines have saved millions, there is clearly room for improvement [43]. Several important considerations point to advantages of a vaccine comprised of multiple proteins [53]. Pneumococci infect many body sites and use organ specific virulence determinants to cause disease [54]. A given protein may have different efficacy protecting the lung, heart or brain. Prevention of colonization may involve yet other proteins and recent evidence suggests that preventing transmission is not equivalent to interrupting colonization [55,56]. This opens the concept of multicomponent vaccines that may have different protective functions to achieve broad anti-Spn immunity. Since capsule-based vaccines are optimized only to induce opsonic antibodies, the abilities of vaccines to protect by other mechanisms are not currently being incorporated into vaccine design strategies. For example, antibodies that aggregate bacteria for more effective clearance, neutralize toxins, or block Spn adherence, invasion, etc. can be induced across serotypes by incorporating proteins into vaccines. This blind spot suggests current designs are missing opportunities to increase the efficacy of existing and future vaccines [57].

The concept that targeting multiple proteins with many functions could lead to broader and potentially superior protection is supported by the mechanism proposed to underpin the broad naturally occurring immunity that develops in young adults. This protection arises by repeated infections, including asymptomatic colonization, experienced throughout childhood and is dependent on the adaptive immune response targeting many Spn antigens (e.g. surface proteins) [58]. Rather than being simply serotype specific, immunity in young adults is a result of an adaptive immune response against a variety of conserved bacterial proteins [53]. Importantly, given the sequence variability in pneumococcal surface proteins, it seems that no one protein antigen is likely to be sufficiently conserved to confer protection on its own.

5. Leading Candidate Proteins

Leading candidate proteins and their location on the pneumococcal surface are shown in Figure 2. Numerous studies with immunized animals show that antibodies against a combination of pneumococcal proteins confers superior protection compared to single antigens [55,59–63]. Key criteria for choosing optimal proteins include: extent of conservation across Spn (and absence in other non-pathogenic streptococci), high in vivo expression across relevant anatomical sites [54], and sufficient surface expression and accessibility suitable for recognition by antibody [64]. Below we discuss the candidate proteins that are being investigated as part of multi-valent protein vaccines either as a mixture or presented as a single recombinant hybrid protein.
Figure 2. Leading candidate proteins for multi-valent vaccines. There are several conserved bacterial proteins—both on the surface of the cell wall (hatched black lines with red teichoic acids) and present in the extracellular environment of the bacteria. Pneumolysin (white star) is a pore forming toxin that is localized within the cytoplasm, but is released during cell lysis. Pneumococcal surface protein A (PspA), choline binding protein (CbpA), pneumococcal choline binding protein (PcpA) and histidine triad protein D (PhtD) are surface proteins that have domains conserved across serotypes and contribute to pneumococcal pathogenesis. Antibodies (pink and red Y shapes) targeting each of these proteins have been shown to convey protection to animals against experimental disease. Thus, they have been formulated into vaccines for human clinical trials.

5.1. Pneumolysin

Pneumolysin is a cholesterol-dependent pore-forming toxin produced by nearly all *S. pneumoniae* [65]. It is produced as a 53kDa soluble monomer [66]. Pneumolysin does not have an N-terminal signal peptide and is thus localized within the cytoplasm. Its release is dependent on death and lysis of the bacteria [67–69]. Upon binding to the host cell membrane, pneumolysin oligomerizes forming a 30–50 subunit pre-pore complex, that subsequently undergoes a conformational shift, becomes hydrophobic, and inserts into the membrane to create a 350–450 Å pore [70,71]. Pore-formation by pneumolysin results in host cell ion-dysregulation which, at low levels, can cause cellular dysfunction, including inhibition of ciliary beating on bronchial epithelial cells, and at higher doses trigger cell death via apoptosis and necroptosis [72,73]. Pneumolysin can kill virtually any host cell. Pneumolysin is one of *S. pneumoniae*’s most potent virulence determinants, and on its own, following intratracheal instillation into a rat lung, was capable of recapitulating the lung injury observed during pneumococcal pneumonia. Pneumolysin has also been shown to induce cochlear damage and hearing loss and aid in immune system avoidance in animal models [66,74,75]. Recently, it has been classified as an important mediator of cardiomyocyte death during disseminated infection [73,76].

From a vaccine perspective, pneumolysin is highly conserved and antigenic. Human studies have shown that exposed individuals generate high antibody titers against pneumolysin [77,78]. Moreover, pneumolysin cytotoxicity can be effectively neutralized by antibody raised against a toxoid version that fails to oligomerize [79]. However, pneumolysin is not present on the bacterial surface in meaningful concentrations and thus antibody against pneumolysin is neutralizing but not opsonic.
5.2. Pneumococcal surface protein A (PspA)

PspA is a member of the pneumococcal choline binding protein family [80]. A C-terminal choline binding domain allows these proteins to non-covalently attach to phosphorylcholine residues found on the teichoic acid of the cell wall (Figure 2). PspA has multiple roles including conferring resistance to lactoferrin killing [81], as well as sterically blocking recognition of phosphorylcholine residues on the bacterial surface that target the bacteria for clearance by the host innate immune component C-reactive protein and complement [82].

As a vaccine candidate, the expression of pspA is constitutive and among those genes with the highest level of expression across five distinct anatomical sites: the nasopharynx, lungs, blood, heart, and kidneys of infected mice by three distinct strains of Spn [54]. Thus, it is a valid protective antigen candidate for antibody-mediated opsonization. In numerous animal studies of immunization followed by direct Spn challenge, antibodies against PspA were sufficient to confer protection [83,84]. The N-terminal domain of PspA is composed of numerous alpha-helices and has considerable variability, sufficient to divide the protein into distinct serological-based clades [85,86]. Protective antibodies can be clade specific or directed to the conserved proline-rich domain found in the majority of PspA versions. Passive protection against pneumococcal sepsis in mice was also seen using antibodies generated from a human clinical safety trial [84,87].

5.3. Choline Binding Protein A (CbpA/PspC)

Another vital choline binding protein is CbpA [80]. CbpA, also known as PspC, has multiple roles in pathogenesis, including functioning as an adhesin/invasin, modulating chemokine responses, and disrupting the alternative complement cascade by binding to Factor H [88–91]. Similar to PspA, CbpA has a polymorphic alpha-helical domain at its N-terminus. However, two domains are broadly conserved and suitable as antigens for a vaccine. The (NEEK) domain binds to host laminin receptor (LR) during bacterial translocation across vascular endothelial cells and the YPT domain binds the polymeric immunoglobulin receptor (pIgR) on mucosal epithelial cells in the upper respiratory tract [88,89,92] (Figures 2 and 3). These interactions induce bacterial uptake into cells via receptor-mediated endocytosis and allow the bacteria to cross to the basolateral side of endothelial or epithelial barriers, respectively. This includes crossing the blood-brain barrier to cause meningitis and trafficking into the heart to cause myocardial injury [59,80,89,93,94].

Similar to pneumolysin and PspA, antibodies against CbpA have been demonstrated to confer protection in animal models. Alone and in combination, the conserved epitopes of CbpA generate antibody-mediated and cell-mediated protection at mucosal sites, during invasive disease, and particularly show promise in protecting the lung, heart and brain [63,89,94–96]. A unique advantage of CbpA as a vaccine antigen is its ability to generate cross protective antibodies to proteins from meningococcus and Haemophilus influenzae that also target LR to promote invasion of the brain during meningitis [89,94].

5.4. Pneumococcal Choline Binding Protein A: PcpA

PcpA, which is unfortunately eponymous to but distinguishable from CbpA, is a 79kDa protein with a C-terminal choline-binding domain and several leucine-rich repeats in its N-terminal [97]. It has been demonstrated to be under the control of a manganese-dependent regulator, PsaR [98]. Thus, it is actively expressed in the blood and lungs and repressed in secretions, where the concentration of manganese is low [98–100]. PcpA plays a role in bacterial adherence to human pharyngeal and lung epithelial cells [101]. Mice infected with PcpA mutants had decreased lung bacterial burden indicating that this protein is important for promoting pneumonia [98]. Using signature-tagged mutagenesis, PcpA mutants showed decreased virulence during mouse pneumonia and sepsis [102]. Mice immunized with PcpA and infected with Spn showed demonstrably lower lung bacterial burdens in a pneumonia model and increased survival in a sepsis model [103,104].
5.5. Histidine Triad Protein D: PhtD

PhtD belongs to the pneumococcal histidine triad family known by the HxxHxH motif that may bind metal or nucleosides [60,105,106]. These proteins help to inhibit C3 deposition on Spn [107]. Specific PhtD antibodies endow protection against sepsis in a serotype and mouse strain dependent manner [106]. Notably, antibodies against PhtD protect mice infected with serotypes 3, 4, 6A, and 6B, but not serotypes 1 and 5 [61,106]. Acute and convalescent sera collected from human infants and adults demonstrated that PhtD antibodies are generated during natural otitis media and bacteremia [106].

6. Why Immunization with More Than One Protein Is Better. A Potential Role for Hybrid Antigens Within the Conjugate Vaccine

6.1. PcpA/PhtD/Pneumolysin

Given the extraordinary success of PCVs in protecting against invasive disease, it is unlikely that capsule-based vaccines will be replaced. Similarly, there does not appear to be a single master pneumococcal protein that would sufficiently expand protection if used in place of CRM197 in conjugate vaccines. Rather, it is more likely that the increasing need for vaccines against non-PCV serotypes will be addressed by multi-protein vaccines used in parallel with PCVs. These protein combinations have several important capabilities not found in PCVs. They can target beyond opsonophagocytosis to different processes in disease (colonization, transmission, attachment/invasion, cell death) and extend protection beyond PCVs to multiple organs and compartments (upper and lower respiratory tract, heart, and brain). Along such lines, the use of recombinant hybrid proteins that elicit protective antibody against more than one pneumococcal protein would be highly favored as it would enhance vaccine efficacy while limiting production costs.

A trivalent vaccine that included PcpA, PhtD and the pneumolysin toxoid PlyD1 (Figure 3A), was extensively tested in mouse models and showed protection from serotypes 6A and 3-induced pneumonia [108] and infant mouse sepsis [109]. Promising results in models against pneumonia and upper respiratory infection, known deficits of PCVs, resulted in enthusiasm for assessing safety and efficacy in human clinical trials. In several Phase I randomized clinical trials, this triad was uniformly safe and antigenic [94,110–115]. Unfortunately, analysis for protection against carriage or otitis media showed no benefit [116–118].
Figure 3. Multivalent protein formulations. (A) The PcpA, PhtD, PlyD1 multivalent vaccine consisting of recombinant PcpA and PhtD along with the PlyD1 pneumolysin toxoid. (B) YLN hybrid construct consisting of the YPT and NEEK conserved domains of CbpA fused with the N- and C-terminus, respectively, of the inactive L460D pneumolysin toxoid. 6.1. PcpA/PhtD/pneumolysin toxoid multivalent vaccine.

6.2. Pneumolysin/CbpA Hybrid (YLN)

YLN (YPT-L460D-NEEK) is a single hybrid protein created by fusing the DNA sequences for two domains of cbpA (YPT, plgR binding domain and NEEK, Laminin receptor binding domain) to a gene for a toxoid of pneumolysin (L460D) (Figure 3B) [63,92,108,109,111–115]. The L460D substitution disrupts the cholesterol recognition motif, thereby strongly reducing cytotoxicity [119]. The vaccine induces antibodies to all three components, including neutralizing wild type toxin and blocking adherence to epithelia and endothelia in invasive disease. In a sepsis mouse model, the mortality of mice vaccinated with YLN was significantly decreased against several pneumococcal strains and this protective phenotype extended to organ specific bacterial burdens as well [63]. Unlike with PCV, the YLN vaccine was demonstrated to be protective against otitis media caused by a non-encapsulated strain [113]. Antibodies against CbpA have been demonstrated to also recognize the LR binding proteins of meningococcus and H. influenzae [94] and thus provide cross protection for meningitis and otitis for three frequent pathogens in these sites [88,92,120]. YLN rabbit antiserum given to mice was effective in a passive protection model against sepsis, meningitis, pneumonia and acute otitis media [89]. YLN is the only vaccine thus far to protect against formation of Spn cardiac microlesions that lead to cardiac mortality following pneumonia [72,121].

6.3. Integrated Approaches

Importantly, one option being considered is that newer versions of the PCV vaccines integrate the use of one or more conserved pneumococcal proteins. Capsular polysaccharide from the serotypes being added to the expanded versions of PCV could be conjugated to an individual or combination of pneumococcal proteins alternatively conjugated to a hybrid protein such as YLN, instead of the currently used carrier protein. Such a vaccine
formulation would have the advantage of conferring strong protection against invasive disease caused by the most problematic serotypes, yet also eliciting broad protection against all other pneumococci. Antibody elicited by the inclusion of a hybrid protein versus a single antigen has the advantage of expanded protection. The ability of antibodies against proteins to confer these protective effects would be complementary to the opsonization occurring as result of the antibody generated to capsule and therefore could take advantage of the non-opsonic properties of antibody as discussed above.

7. Live and Whole Cell Vaccines as Alternatives

The concept of immunization with multiple proteins can also be achieved by the older strategy of using live or killed intact bacteria. This approach has lost favor as it may result in presentation of unwanted toxic components and technological and genetic advances have allowed isolation of purified proteins. However, these advancements do not diminish the ability of intact cells to invoke serotype-independent immunity. If more advanced strategies fail in the clinic, this approach may be a backup to development of protein vaccines. As expected, intact bacteria, whether alive or heat-killed, induce robust antibodies to many proteins.

At least four live vaccines have been studied using several methods of attenuation such as replacing the pneumolysin gene with a toxoid or deleting genes needed for bacterial metabolism in vivo [56]. Should these vaccines establish a long enough residence time upon inoculation in the nasopharynx, this approach has advantages in presenting antigens to the mucosal surface directly at this entry site. Concerns regarding the feasibility of live vaccines are that the individuals who most benefit by vaccination against *Sps* are those that are the relatively immunocompromised, e.g., very young children, elderly, and individuals with genetic disorders such as sickle-cell disease. The possibility of an attenuated vaccine strain regaining virulence through genetic recombination is also to be considered. Thus, a live vaccine has inherent risks that might not make it tractable.

Two killed unencapsulated whole cell vaccines have been in development. One bears a pneumolysin toxoid gene and a deletion in the major autolysin and the other is a gamma irradiated intact bacterium [122,123]. Both raise antibodies and T cells to a broad array of antigens and are protective in animal models of sepsis and carriage [124]. The former has been reported to be safe and immunogenic in Phase I human trials [125]. There is a significant cost advantage to this simple approach and if side effects prove to be minimal, it may be an important addition to vaccination in the underdeveloped world.

8. Conclusions

Pneumococcus has been recognized as a leading cause of morbidity and mortality for over a century. As a result, polysaccharide-based vaccines (PPSV and PCV) were pioneered against this infection to massive success. Although currently licensed PCV is often thought of as the “gold standard”, serotype replacement and other limitations demand a new, potentially added approach—in particular, serious consideration is being given to a protein-based vaccine that confers broad serotype-independent protection. As discussed, a protein-based vaccine has the potential to provide increased respiratory tract protection, prevent invasion of specific organs, neutralize pneumolysin cytotoxicity, provide cross protection against additional childhood pathogens and mitigate adverse complications arising from disseminated bacterial infection. The hope is that promising protein-based vaccines will mount protective and long-lasting memory that is conserved across pneumococcal serotypes.

**Author Contributions:** Conceptualization, N.R.S., E.I.T., and C.J.O.; writing—original draft preparation, N.R.S., E.I.T., and C.J.O.; writing—review and editing, N.R.S., E.I.T., and C.J.O.; visualization B.M., E.I.T., and C.J.O. All authors have read and agreed to the published version of the manuscript.
**Funding:** This research was funded by NIH grant AI128756 and ALSAC to E.I.T. Additionally, by NIH grants AI114800, AI146149, AI148368 and AI156898 as well as American Heart Association grant 18TPA3411095 to C.J.O. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the review.

**Conflicts of Interest:** B.M., E.I.T., and C.J.O. hold patents on Y.L.N. and receive licensing fees in regard to development of a vaccine antigen.

**References**

1. Hoffman, J.A.; Mason, E.O.; Schutze, G.E.; Tan, T.Q.; Barson, W.J.; Givner, L.B.; Wald, E.R.; Bradley, J.S.; Yoge, R.; Kaplan, S.L. *Streptococcus pneumoniae* infections in the neonate. *Pediatrics* 2003, 112, 1095–1102. doi:10.1542/peds.112.5.1095.

2. Stupka, J.E.; Mortensen, E.M.; Anzueto, A.; Restrepo, M.I. Community-acquired pneumonia in elderly patients. *Aging Heal* 2009, 5, 763–774. doi:10.2217/ah.09.74.

3. Morrill, H.J.; Caffrey, A.R.; Noh, E.; Laplante, K.L. Epidemiology of pneumococcal disease in a national cohort of older adults. *Infect. Dis. Ther.* 2014, 3, 19–33. doi:10.1007/s10121-014-0025-y.

4. van Aalst, M.; Löttsch, F.; Spijker, R.; van der Meer, J.T.M.; Langendam, M.W.; Goorhuis, A.; Grobusch, M.P.; de Bree, G.J. Incidence of invasive pneumococcal disease in immunocompromised patients: a systematic review and meta-analysis. *Travel. Med. Infect. Dis.* 2018, 24, 89–100.

5. Backhaus, E.; Berg, S.; Andersson, R.; Ockborn, G.; Malmström, P.; Dahl, M.; Nasic, S.; Trollfors, B. Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors. *BMC Infect. Dis.* 2016, 16, 367.

6. Regev-Yochay, G.; Raz, M.; Dağan, R.; Porat, N.; Shainberg, B.; Pinco, E.; Keller, N.; Rubinstein, E. Nasopharyngeal carriage of *Streptococcus pneumoniae* by adults and children in community and family settings. *Clin. Infect. Dis.* 2004, 38, 632–639.

7. Wahl, B.; O’Brien, K.L.; Greenbaum, A.; Majumder, A.; Liu, L.; Chu, Y.; Lukšić, I.; Nair, H.; McAllister, D.A.; Campbell, H.; et al. Burden of *Streptococcus pneumoniae* and *Haemophilus influenzae* type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. *Lancet Glob. Heal.* 2018, 6, e744–e757. doi:10.1016/s2214-109x(18)30247-x.

8. Troeger, C.; Forouzanfar, M.; Rao, P.C.; Khalil, I.; Brown, A.; Swartz, S.; Fullman, N.; Mosser, J.; Thompson, R.L.; Reiner, R.C.; et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: A systematic analysis for the Global Burden of Disease Study 2015. *Lancet Infect. Dis.* 2017, 17, 1133–1161. doi:10.1016/s1473-3099(17)30396-1.

9. Ganaie, F.; Saad, J.S.; McGee, L.; Van Tonder, A.J.; Bentley, S.D.; Lo, S.W.; Gladstone, R.A.; Turner, P.; Keenan, J.D.; Breiman, R.F.; et al. A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral streptococcus. *mBio* 2020, 11, 00937–00920. doi:10.1128/mbio.00092-20.

10. Weiser, J.N.; Ferreira, D.M.; Paton, J.C. *Streptococcus pneumoniae*: transmission, colonization and invasion. *Nat. Rev. Genet.* 2018, 19, 355–367. doi:10.1038/s41579-018-0001-8.

11. Li, Y.; Weinberger, D.M.; Thompson, C.M.; Trzciński, K.; Lipsitch, M. Surface charge of *Streptococcus pneumoniae* predicts serotype distribution. *Infect. Immun.* 2013, 81, 4519–4524. doi:10.1128/iai.00724-13.

12. Walsh, R.L.; Camilli, A. *Streptococcus pneumoniae* is desiccation tolerant and infectious upon rehydration. *mBio* 2011, 2, e00092–11. doi:10.1128/mbio.00092-11.

13. Melin, M.; Trzcinski, K.; Meri, S.; Käyhty, H.; Vakeväinen, M. The capsular serotype of *Streptococcus pneumoniae* is more important than the genetic background for resistance to complement. *Infect. Immun.* 2010, 78, 5262–5270. doi:10.1128/iai.00740-10.

14. de Vos, A.F.; Dessing, M.C.; Lammers, A.J.; de Porto, A.P.; Florquin, S.; de Boer, O.J.; de Beer, R.; Terpstra, S.; Bootma, H.J.; Hermans, P.W.; et al. The polysaccharide capsule of *Streptococcus pneumoniae* partially impedes MyD88-mediated immunity during pneumonia in mice. *PLoS ONE* 2015, 10, e0118181.

15. Hathaway, L.J.; Grandgirard, D.; Valente, L.G.; Täuber, M.G.; Leib, S.L. *Streptococcus pneumoniae* capsule determines disease severity in experimental pneumococcal meningitis. *Open Biol.* 2016, 6, 150269. doi:10.1098/rsob.150269.

16. Geno, K.A.; Gilbert, G.L.; Song, J.Y.; Skovstved, I.C.; Klugman, K.P.; Jones, C.; Konradsen, H.B.; Nahm, M.H. Pneumococcal capsules and their types: past, present, and future. *Clin. Microbiol. Rev.* 2015, 28, 871–899. doi:10.1128/cmr.00024-15.

17. Hyams, C.; Camberlein, E.; Cohen, J.M.; Bax, K.; Brown, J.S. The *Streptococcus pneumoniae* capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. *Infect. Immun.* 2010, 78, 704–715.

18. Keller, L.E.; Robinson, D.A.; McDaniel, L.S. Nomenencapsulated *Streptococcus pneumoniae*: emergence and pathogenesis. *mBio* 2016, 7, e01792-15. doi:10.1128/mBio.01792-15.

19. Hamborsky, J.; Kroger, A. Epidemiology and prevention of vaccine-preventable diseases, E-Book: The Pink Book. Public Health Foundation. 2015. Available online: https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html (accessed on 26 January 2021).

20. Wright, A.; Parry, M.W.; Colebrook, L.; Dodgson, R.W. Observations on prophylactic inoculation against pneumococcus infections and the results of which have been achieved by it. *Lancet* 1914, 183, 87–95.

21. MacLeod, C.M.; Hodges, R.G.; Heidelberger, M.; Bernhard, W.G. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. *J. Exp. Med.* 1945, 82, 445–465. doi:10.1084/jem.82.6.445.
22. Daniels, C.C.; Rogers, P.D.; Shelton, C.M. A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens. J. Pediatr. Pharmacol. Ther. 2016, 21, 27–35, doi:10.5863/1551-6776-21.1.27.

23. Alicino, C.; Pagano, C.; Orsi, A.; Astengo, M.; Trucchi, C.; Icardi, G.; Ansaldi, F. The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on hospitalization for pneumonia in children: a systematic review and meta-analysis. Vaccine 2017, 35, 5776–5785, doi:10.1016/j.vaccine.2017.09.005.

24. Jackson, L.A.; Neuzil, K.M.; Yu, O.; Benson, P.; Barlow, W.E.; Adams, A.L.; Hanson, C.A.; Mahoney, L.D.; Shlay, D.K.; Thompson, W.W. Effectiveness of pneumococcal polysaccharide vaccine in older adults. New Engl. J. Med. 2003, 348, 1747–1755, doi:10.1056/nejmol02678.

25. Feldman, C.; Anderson, R. Review: Current and new generation pneumococcal vaccines. J. Infect. 2014, 69, 309–325, doi:10.116/j.jinf.2014.06.006.

26. Zarei, A.E.; Almedhar, H.A.; Redwan, E.M. Hib vaccines: past, present, and future perspectives. J. Immunol. Res. 2016, 2016, 1–18, doi:10.1155/2016/7203587.

27. Wiese, A.D.; Griffin, M.R.; Grijalva, C.G. Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States. Expert Rev. Vaccines 2019, 18, 327–341, doi:10.1080/14760584.2019.1582337.

28. Grijalva, C.G.; Nuorti, J.P.; Arbogast, P.G.; Martin, S.W.; Edwards, K.M.; Griffin, M.R. Decline in pneumonia admissions after routine childhood immunization with pneumococcal conjugate vaccine in the USA: A time-series analysis. Lancet 2007, 369, 1179–1186, doi:10.1016/s0140-6736(07)60564-9.

29. Zhou, F.; Kyaw, M.H.; Shefer, A.; Winston, C.A.; Nuorti, J.P. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch. Pediatr. Adolesc. Med. 2007, 161, 1162–1168, doi:10.1001/archpedi.161.12.1162.

30. Barricarte, A.; Castilla, J.; Gil Setas, A.; Torroba, L.; Alonso, J.A.N.; Irisarri, F.; Arriazu, M. Effectiveness of the 7-Valent Pneumococcal Conjugate Vaccine: A population-based case-control study. Clin. Infect. Dis. 2007, 44, 1436–1441, doi:10.1086/s1516779.

31. van der Linden, M.; Falkenhorst, G.; Periniciaro, S.; Imöhl, M. Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany. PLoS ONE 2015, 10, e0131494.

32. Feikin, D.R.; Kagucia, E.W.; Loo, J.D.; Link-Gelles, R.; Puhan, M.A.; Cherian, T.; Levine, O.S.; Whitney, C.G.; O’Brien, K.L.; Moore, M.R.; et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013, 10, e1001517, doi:10.1371/journal.pmed.1001517.

33. Bonten, M.J.; Huijts, S.M.; Bolkenbaas, M.; Webber, C.; Patterson, S.; Gault, S.; Van Werkhoven, C.H.; Van Deursen, A.M.; Sanders, E.A.; Verheij, T.J.; et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. New Engl. J. Med. 2019, 372, 1114–1125, doi:10.1056/nejmoa190454.

34. Fattom, A.; Cho, Y.H.; Chu, C.; Fuller, S.; Fries, L.; Naso, R. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vaccine 1999, 17, 126–133, doi:10.1016/s0264-410x(98)00162-5.

35. Carter, R.; Wolf, J.; Van Opijnen, T.; Muller, C.; Obert, C.; Burnham, C.; Mann, B.; Li, Y.; Hayden, R.T.; Pestina, T.; et al. Genomic analyses of pneumococci from children with sickle cell disease expose host-specific bacterial adaptations and deficits in current interventions. Cell Host Microbe 2014, 15, 587–599, doi:10.1016/j.chom.2014.04.005.

36. Hicks, L.A.; Harrison, L.H.; Flannery, B.; Hadler, J.L.; Schaffner, W.; Craig, A.S.; Jackson, D.; Thomas, A.; Beall, B.; Lynfield, R.; et al. Incidence of pneumococcal disease due to non–pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J. Infect. Dis. 2007, 196, 1346–1354, doi:10.1086/521626.

37. Lachen, A.; Croucher, N.J.; Anderson, R.M. Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency. Sci. Rep. 2020, 10, 1–17, doi:10.1038/s41598-020-75691-5.

38. Control CiD. Drug Resistance. 2020. Available online: https://www.cdc.gov/Pneumococcal/Drug-Resistance.html (accessed on: 26 January 2021).

39. De Croo, M.S.; Mitsu, E.; Morozov, A.; Glenn, S.; Andrew, P.W.; Ferreira, D.; Ioppioni, M.R. Phase variation in pneumococcal populations during carriage in the human nasopharynx. Sci. Rep. 2020, 10, 1803.

40. Kietzman, C.C.; Gao, G.; Mann, B.; Myers, L.; Tuomanen, E.I. Dynamic capsule restructuring by the main pneumococcal auto-lysin LytA in response to the epithelium. Nat. Commun. 2016, 7, 10859, doi:10.1038/ncomms10859.

41. Luck, J.N.; Tettelin, H.; Orihuela, C.J. Sugar-Coated Killer: Serotype 3 pneumococcal disease. Front. Cell. Infect. Microbiol. 2020, 10, 613287, doi:10.3389/fcimb.2020.613287.

42. Choi, E.H.; Zhang, F.; Lu, Y.J.; Malley, R. Capsular Polysaccharide (CPS) Release by serotype 3 pneumococcal strains reduces the protective effect of anti-type 3 CPS antibodies. Clin. Vaccine Immunol. 2015, 23, 162–167, doi:10.1128/cvi.00591-15.

43. Andrews, N.J.A.; Waigh, P.; Burbidge, P.; Pearce, E.; Roalé, L.; Zancoll, M.; Slack, M.; Ladhani, S.N.; Miller, E.; Goldblatt, D. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: A postlicensure indirect cohort study. Lancet Infect. Dis. 2014, 14, 839–846, doi:10.1016/s1473-3099(14)70822-9.

44. Africano, H.F.; Serrano-Mayorga, C.C.; Ramirez-Valbuena, P.C.; Bustos, I.G.; Bastidas, A.A.; Vargas, H.; Gómez, S.; Rodriguez, A.; Orihuela, C.J.; Reyes, L.F. Major adverse cardiovascular events during invasive pneumococcal disease are serotype dependent. Clin. Infect. Dis. 2020, doi:10.1093/cid/ciaa1427.
69. Price, K.E.; Camilli, A. Pneumolysin localizes to the cell wall of Streptococcus pneumoniae. J. Bacteriol. 2009, 191, 2163–2168, doi:10.1128/jb.01489-08.

70. Alouf, J. Cholesterol-binding cytolytic protein toxins. Int. J. Med. Microbiol. 2000, 290, 351–356, doi:10.1016/s1438-4221(00)80039-9.

71. Gilbert, R.J.; Jiménez, J.L.; Chen, S.; Tickle, I.J.; Rossjohn, J.; Parker, M.; Andrew, P.W.; Saibil, H.R. Two structural transitions in membrane pore formation by pneumolysin, the pore-forming toxin of Streptococcus pneumoniae. Cell 1999, 97, 647–655, doi:10.1016/s0092-8674(00)80778-8.

72. Beno, S.M.; Riegler, A.N.; Gilley, R.P.; Brissac, T.; Wang, Y.; Kruckow, K.L.; Jadapalli, J.K.; Wright, G.M.; Shenoy, A.T.; Stoner, S.N.; et al. Inhibition of necroptosis to prevent long-term cardiac damage during pneumococcal pneumonia and invasive disease. J. Infect. Dis. 2020, 222, 1882–1893, doi:10.1093/infdis/jiaa295.

73. González-Juarbe, N.; Bradley, K.M.; Shenoy, A.T.; Gilley, R.P.; Reyes, L.F.; Hinojosa, C.A.; Restrepo, M.I.; Dube, P.H.; Bergman, M.A.; Orihuela, C.J. Pore-forming ion-mediated ion dysregulation leads to death receptor-independent necroptosis of lung epithelial cells during bacterial pneumonia. Cell Death Differ. 2017, 24, 917–928, doi:10.1038/cdd.2017.49.

74. Beurg, M.; Hafidi, A.; Skinner, L.; Cowan, G.; Hondarague, Y.; Mitchell, T.J.; Dunol, D. The mechanism of pneumolysin-induced cochlear hair cell death in the rat. J. Physiol. 2005, 568, 211–227, doi:10.1111/j.physiol.2005.092478.

75. Wittenrath, M.; Pache, F.; Lorenz, D.; Koppe, U.; Gutbier, B.; Tabeling, C.; Reppe, K.; Meixenberger, K.; Dorhoi, A.; Ma, J.T.; et al. The NLRP3 inflammasome is differentially activated by pneumolysin variants and contributes to host defense in pneumococcal pneumonia. J. Immunol. 2011, 187, 434–440, doi:10.4049/jimmunol.1003143.

76. Alhamdi, Y.; Neill, D.R.; Abrams, S.T.; Malak, H.A.; Yahya, R.; Barrett-Jolley, R.; Wang, G.; Kadioglou, A.; Toh, C.-H. Circulating pneumolysin is a potent inducer of cardiac injury during pneumococcal infection. PLOS Pathog. 2015, 11, e1004836, doi:10.1371/journal.ppat.1004836.

77. Huo, Z.; Spencer, O.; Miles, J.; Johnson, J.; Holliman, R.; Sheldon, J.; Riches, P. Antibody response to pneumolysin and to pneumococcal capsular polysaccharide in healthy individuals and Streptococcus pneumoniae infected patients. Vaccine 2004, 22, 1157–1161, doi:10.1016/j.vaccine.2003.09.025.

78. Musher, D.M.; Phan, H.M.; Baughn, R.E. Protection against bacteremic pneumococcal infection by antibody to pneumolysin. J. Infect. Dis. 2001, 183, 827–830, doi:10.1086/318833.

79. Salha, D.; Szojo, J.; Myers, L.; Claus, C.; Sheung, A.; Tang, M.; Lujtic, B.; Hanwell, D.; Ogilvie, K.; Ming, M.; et al. Neutralizing antibodies elicited by a novel detoxified pneumolysin derivative, PlyD1, provide protection against both pneumococcal infection and lung injury. Infect. Immun. 2012, 80, 2212–2220, doi:10.1128/iai.00368-11.

80. Rosenow, C.; Ryan, P.; Weiser, J.N.; Johnson, S.; Fontan, P.; Ortvqvist, A.; Masure, H.R. Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol. Microbiol. 1997, 25, 819–829, doi:10.1111/j.1365-2958.1997.mmi494.x.

81. Hammerschmidt, S.; Bethe, G.; Remane, P.H.; Chhatwal, G.S. Identification of pneumococcal surface protein A as a lactoferrin-binding protein of Streptococcus pneumoniae. Infect. Immun. 1999, 67, 1683–1687.

82. Mukerji, R.; Mirza, S.; Roche, A.M.; Widener, R.W.; Croney, C.M.; Rhee, D.-K.; Weiser, J.N.; Szalai, A.J.; Briles, D.E. Pneumococcal Surface Protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C- Reactive Protein to cell-surface phospholipase. J. Immunol. 2012, 189, 5327–5335, doi:10.4049/jimmunol.1201967.

83. Coats, M.T.; Benjamin, W.H.; Hollingshead, S.K.; Briles, D.E. Antibodies to the pneumococcal surface protein A, PspA, can be produced in splenectomized and can protect splenectomized mice from infection with Streptococcus pneumoniae. Vaccine 2005, 23, 4257–4262.

84. Briles, D.E.; Hollingshead, S.K.; King, J.; Swift, A.; Braun, P.A.; Park, M.K.; Ferguson, L.M.; Nahm, M.H.; Nabors, G.S. Immunization of Humans with Recombinant Pneumococcal Surface Protein A (rPspA) Elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J. Infect. Dis. 2000, 182, 1694–1701, doi:10.1086/317602.

85. Hollingshead, S.K.; Becker, R.; Briles, D.E. Diversity of PspA: Mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect. Immun. 2000, 68, 5889–5900, doi:10.1128/iai.68.10.5889-5900.2000.

86. Rolo, D.; Ardanuy, C.; Fleites, A.; Martin, R.; Liñares, J. Diversity of pneumococcal surface protein A (PspA) among prevalent clones in Spain. BMC Microbiol. 2009, 9, 80, doi:10.1186/1471-2180-9-80.

87. Nabors, G.S.; Braun, P.A.; Herrmann, D.J.; Heise, M.L.; Pyle, D.J.; Gravenstein, S.; Schilling, M.; Ferguson, L.M.; Hollingshead, S.K.; Briles, D.E.; et al. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 2000, 18, 1743–1754, doi:10.1016/s0264-410x(99)00530-7.

88. Lu, L.; Lamm, M.E.; Li, H.; Corthesy, B.; Zhang, J.-R. The human polymeric immunoglobulin receptor binds to Streptococcus pneumoniae via Domains 3 and 4. J. Biol. Chem. 2003, 278, 48178–48187, doi:10.1074/jbc.m306906200.

89. Orihuela, C.J.; Mahdavi, J.; Thornton, J.; Mann, B.; Wooldridge, K.G.; Abouseada, N.; Oldfield, N.J.; Self, T.; A1a’Aldeen, D.A.; Tuomanen, E.I. Laminin receptor initiates bacterial contact with the blood brain barrier in experimental meningitis models. J. Clin. Investig. 2009, 119, 1638–1646, doi:10.1172/jci36799.

90. Lu, L.; Ma, Y.; Zhang, J.-R. Streptococcus pneumoniae recruits Complement Factor H through the amino terminus of CbpA. J. Biol. Chem. 2006, 281, 15464–15474, doi:10.1074/jbc.m602404200.
Vaccines 2021, 9, 209

91. Graham, R.M.A.; Paton, J.C. Differential role of CbpA and PspA in modulation of in vitro CXC chemokine responses of respiratory epithelial cells to infection with Streptococcus pneumoniae. Infect. Immun. 2006, 74, 6739–6749, doi:10.1128/iai.00954-06.

92. Zhang, J.R.; Mostov, K.E.; Lamm, M.E.; Nanno, M.; Shimida, S.; Ohwaki, M.; Tuomanen, E. The polymeric immunoglobulin receptor translocates pneumococci across human nasopharyngeal epithelial cells. Cell 2002, 102, 827–837.

93. Orihuela, C.J.; Gao, G.; Francis, K.P.; Yu, J.; Tuomanen, E.I. Tissue-specific contributions of pneumococcal virulence factors to pathogenesis. J. Infect. Dis. 2004, 190, 1661–1669, doi:10.1086/424596.

94. Mann, B.; Thornton, J.; Heath, R.; Wade, K.R.; Tweten, R.K.; Gao, G.; El Kasmi, K.; Jordan, J.B.; Mitrea, D.M.; Kriwacki, R.; et al. Broadly protective protein-based pneumococcal vaccine composed of pneumolysin toxoid-CbpA peptide recombinant fusion protein. J. Infect. Dis. 2014, 209, 1116–1125.

95. Ogunniyi, A.D.; Woodrow, M.C.; Poolman, J.T.; Paton, J.C. Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infect. Immun. 2001, 69, 5997–6003, doi:10.1128/iai.69.10.5997-6003.2001.

96. Balachandran, P.; Brooks-Walter, A.; Virolainen-Julkunen, A.; Hollingshead, S.K.; Briles, D.E. Role of pneumococcal Surface Protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect. Immun. 2002, 70, 2526–2534, doi:10.1128/iai.70.5.2526-2534.2002.

97. Sánchez-Beato, A.R.; López, R.; García, J.L. Molecular characterization of PcpA: A novel choline-binding protein of Streptococcus pneumoniae. FEMS Microbiol. Lett. 1999, 164, 207–214.

98. Johnston, J.W.; Briles, D.E.; Myers, L.E.; Hollingshead, S.K. Mn2+-dependent regulation of multiple genes in Streptococcus pneumoniae through PsaR and the resultant impact on virulence. Infect. Immun. 2006, 74, 1171–1180, doi:10.1128/iai.74.2.1171-1180.2006.

99. Scheuhammer, A.; Cherial, M. Binding of manganese in human and rat plasma. Biochim. Biophys. Acta (BBA)-Gen. Subj. 1985, 840, 163–169, doi:10.1016/0304-4165(85)90115-1.

100. Jakubovics, N.S.; Jenkinson, H.F. Out of the iron age: New insights into the critical role of manganese homeostasis in bacteria. Microbiology 2001, 147, 1709–1718, doi:10.1099/00221287-147-7-1709.

101. Khan, M.N.; Sharma, S.K.; Fiklins, L.M.; Pichichero, M.E. PcpA of Streptococcus pneumoniae mediates adherence to nasopharyngeal and lung epithelial cells and elicits functional antibodies in humans. Microbes Infect. 2012, 14, 1102–1110, doi:10.1016/j.micinf.2012.06.007.

102. Hava, D.I.; Camilli, A. Large-scale identification of serotype 4 Streptococcus pneumoniae virulence factors. Mol. Microbiol. 2002, 45, 1389–1406.

103. Glover, D.T.; Hollingshead, S.K.; Briles, D.E. Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis. Infect. Immun. 2008, 76, 2767–2776, doi:10.1128/iai.01126-07.

104. Walker, M.M.; Novak, L.; Widener, R.; Grubbs, J.A.; King, J.; Hale, J.Y.; Ochs, M.M.; Myers, L.E.; Briles, D.E.; Deshane, J. PcpA promotes higher levels of infection and modulates recruitment of myeloid-derived suppressor cells during pneumococcal pneumonia. J. Immunol. 2016, 196, 2239–2248, doi:10.4049/jimmunol.1402518.

105. Zhang, Y.; Masi, A.W.; Barniaj, V.; Mountzouros, K.; Hostetter, M.K.; Green, B.A. Recombinant PhpA protein, a unique histidine motif-containing protein from Streptococcus pneumoniae, protects mice against intranasal pneumococcal challenge. Infect. Immun. 2001, 69, 3827–3836, doi:10.1128/iai.69.6.3827-3836.2001.

106. Adamou, J.E.; Heinrichs, J.H.; Erwin, A.L.; Walsh, W.; Gayle, T.; Dormitzer, M.; Dagan, R.; Brewah, Y.A.; Barren, P.; Lathigra, R.; et al. Identification and characterization of a novel family of pneumococcal proteins that Are protective against sepsis. Infect. Immun. 2001, 69, 949–958, doi:10.1128/iai.69.6.949-958.2001.

107. Melin, M.; Jarva, H.; Sira, L.; Meri, S.; Käyhty, H.; Väkeväinen, M. Streptococcus pneumoniae capsular Serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than Serotype 6B. Infect. Immun. 2008, 77, 676–684, doi:10.1128/iai.01186-08.

108. Verhoeven, D.; Xu, Q.; Pichichero, M.E. Vaccination with a Streptococcus pneumoniae trivalent recombinant PcpA, PhtD and PlyD1 protein vaccine candidate protects against lethal pneumonia in an infant murine model. Vaccine 2014, 32, 3205–3210, doi:10.1016/j.vaccine.2014.04.004.

109. Xu, Q.; Suren dran, N.; Verhoeven, D.; Klapa, J.; Ochs, M.; Pichichero, M.E. Trivalent pneumococcal protein recombinant vaccine protects against lethal Streptococcus pneumoniae pneumonia and correlates with phagocytosis by neutrophils during early pathogenesis. Vaccine 2015, 33, 993–1000, doi:10.1016/j.vaccine.2015.01.014.

110. Leroux-Roels, G.; Maes, C.; De Boever, F.; Traskine, M.; Rüggeberg, J.U.; Borys, D. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: A phase I/II randomized clinical study. Vaccine 2014, 32, 6838–6846, doi:10.1016/j.vaccine.2014.02.052.

111. Bologa, M.; Kamthoua, T.; Hopfer, R.; Sheng, X.; Hicks, B.; Bixler, G.; Hou, V.; Pehlic, V.; Yuan, T.; Gurunathan, S. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA–pneumococcal histidine triad protein D vaccine. Vaccine 2012, 30, 7461–7468, doi:10.1016/j.vaccine.2012.10.076.

112. Seiberling, M.; Bologa, M.; Brookes, R.; Ochs, M.; Go, K.; Neveu, D.; Kamthoua, T.; Lashley, P.; Yuan, T.; Gurunathan, S. Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults. Vaccine 2012, 30, 7455–7460, doi:10.1016/j.vaccine.2012.10.080.

113. Rowe, H.M.; Mann, B.; Iverson, A.; Poole, A.; Tuomanen, E.; Rosch, J.W. A cross-reactive protein vaccine combined with PCV13 prevents Streptococcus pneumoniae and Haemophilus influenzae-mediated acute otitis media. Infect. Immun. 2019, 87, 00253–00219, doi:10.1128/iai.00253-19.
114. Brooks, W.A.; Chang, L.-J.; Sheng, X.; Hopfer, R. Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: a phase I randomized controlled study. *Vaccine* 2015, 33, 4610–4617, doi:10.1016/j.vaccine.2015.06.078.

115. Kirkham, L.-A.S.; Wiertsema, S.P.; Corscadden, K.J.; Mateus, T.; Mullaney, G.L.; Zhang, G.; Richmond, P.C.; Thornton, R.B. Otitis-prone children produce functional antibodies to pneumolysin and pneumococcal polysaccharides. *Clin. Vaccine Immunol.* 2016, 24, e00497–16, doi:10.1128/cvi.00497–16.

116. Hammitt, L.L.; Campbell, J.C.; Borys, D.; Weatherholtz, R.C.; Reid, R.; Goklish, N.; Moulton, L.H.; Traskine, M.; Song, Y.; Swanen, K.; et al. Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: A phase IIb randomized study. *Vaccine* 2019, 37, 7482–7492, doi:10.1016/j.vaccine.2019.09.076.

117. Odutola, A.; Ota, M.O.; Antonio, M.; Ogundare, E.O.; Saidu, Y.; Foster-Nyarko, E.; Owiafe, P.K.; Ceesay, F.; Worwui, A.; Idoko, O.T.; et al. Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of *Streptococcus pneumoniae* in infants: A phase 2, randomized, controlled, observer-blind study. *Vaccine* 2017, 35, 2531–2542, doi:10.1016/j.vaccine.2017.03.071.

118. Kamtchoua, T.; Bologa, M.; Hopfer, R.; Neveu, D.; Hu, B.; Sheng, X.; Corde, N.; Pouzet, C.; Zimmermann, G.; Gurunathan, S. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults. *Vaccine* 2013, 31, 327–333, doi:10.1016/j.vaccine.2012.11.005.

119. Farrand, A.J.; Lachapelle, S.; Hotze, E.M.; Johnson, A.E.; Tewet, R.K. Only two amino acids are essential for cytolytic toxin recognition of cholesterol at the membrane surface. *Proc. Natl. Acad. Sci. USA* 2010, 107, 4341–4346.

120. Smith, B.L.; Hostetter, M.K.; Rogers, P.D.; Stiles, J.K.; Chapman, S.W.; Cleary, J.D. C3 as Substrate for Adhesion of *Streptococcus pneumoniae*. *J. Infect. Dis.* 2000, 182, 497–508, doi:10.1086/315722.

121. Brissac, T.; Shenoy, A.T.; Patterson, L.A.; Orihuela, C.J. Cell invasion and pyruvate oxidase-derived H2O2 are critical for *Streptococcus pneumoniae*-mediated cardiomyocyte killing. *Infect. Immun.* 2017, 86, e00569-17, doi:10.1128/iai.00569-17.

122. Malley, R.; Lipsitch, M.; Stack, A.; Saladino, R.; Fleisher, G.; Pelton, S.; Thompson, C.; Briles, D.; Anderson, P. Intranasal immunization with killed unicapsulated whole cells prevents colonization and invasive disease by capsulated Pneumococci. *Infect. Immun.* 2001, 69, 4870–4873, doi:10.1128/iai.69.8.4870-4873.2001.

123. Babb, R.; Chen, A.; Hirst, T.R.; Kara, E.E.; McColl, S.R.; Ogurniyi, A.D.; Paton, J.C.; Alsharifi, M. Intranasal vaccination with γ-irradiated *Streptococcus pneumoniae* whole-cell vaccine provides serotype-independent protection mediated by B-cells and innate IL-17 responses. *Clin. Sci.* 2016, 130, 697–710.

124. Campo, J.J.; Le, T.Q.; Pablo, J.V.; Hung, C.; Teng, A.A.; Tettelin, H.; Tate, A.; Hanage, W.P.; Alderson, M.R.; Liang, X.; et al. Panproteome-wide analysis of antibody responses to whole cell pneumococcal vaccination. *eLife* 2018, 7, 7, doi:10.7554/elife.37015.

125. Keech, C.A.; Morrison, R.; Anderson, P.; Tate, A.; Flores, J.; Goldblatt, D.; Briles, D.; Hural, J.; Malley, R.; Alderson, M.R. A phase I randomized, placebo-controlled, observer-blinded trial to evaluate the safety and immunogenicity of inactivated *Streptococcus pneumoniae* whole-cell vaccine in adults. *Pediatr. Infect. Dis. J.* 2020, 39, 345–351, doi:10.1097/inf.0000000000002567.